novel egfr inhibitors in the setting of acquired resistance
Published 9 years ago • 718 plays • Length 26:27Download video MP4
Download video MP3
Similar videos
-
24:36
treatment options for egfr t790m negative acquired resistance
-
3:07
third generation egfr tkis for acquired resistance
-
2:26
patterns of acquired resistance to egfr tkis in egfr mutation-positive nsclc
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
3:24
options for egfr mutation-positive patients with t790m mutation-negative acquired resistance
-
28:17
segment 1: egfr tkis in nsclc
-
5:04
gefitinib: inhibitor of egfr tyrosine kinase mutants in nsclc
-
4:10
egfr mutations in advanced nsclc - targeted therapies in lung cancer 2023
-
12:58
egfr inhibitor therapy in second line
-
9:28
asco 2021 lung: amivantamab lazertinib in egfr, patritumab deruxtecan in egfr acquired resistance
-
11:36
azd9291 for acquired resistance in egfr positive lung cancer
-
11:23
2020 ttf egfr breakout piotrowska part 1 - current options upon acquired resistance to osimertinib
-
18:44
2020 ttf egfr breakout piotrowska part 2 - current options upon acquired resistance to osimertinib
-
29:24
gracecast-068_lung-cancer_sequist on acquired resistance to egfr
-
1:17:52
egfr initial treatment, acquired resistance and q&a with h. jack west, md and helena yu, md
-
1:01
dr. philip bonomi: gefitinib and later generations of egfr inhibitors
-
4:26
combinations and other options for acquired resistance in egfr mutation-positive nsclc
-
1:59
what is egfr and the egfr mutation?
-
4:10
3rd generation drug for acquired resistance in egfr lung cancer
-
2:00
ceritinib and other second generation alk inhibitors for acquired resistance in alk-positive nsclc
-
6:03
gracecastuc-020_lung_case in point: how should we approach someone with a rare egfr mutation?
-
5:09
should a third generation egfr inhibitor be first line therapy for egfr mutation-positive nsclc?